Entacapone — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Parkinson's Disease

• Amantadine
• Carbidopa-Levodopa
• Pramipexole
• Ropinirole

Other medications in Neurological

• Eptinezumab
• Erenumab
• Eslicarbazepine
• Felbamate
• Fenfluramine
• Fingolimod
• Fosphenytoin
• Fremanezumab

About Entacapone

Entacapone is a vital medication for many living with Parkinson's disease, helping to extend the benefits of other therapies. Managing chronic conditions can be costly, but with TheDrugClub, accessing your essential medications like entacapone doesn't have to be a financial burden. Entacapone is a medication primarily used as an adjunct therapy for individuals with Parkinson's disease who are taking levodopa/carbidopa. Its main purpose is to help manage the "wearing-off" phenomenon, a common challenge where the effects of levodopa diminish before the next scheduled dose, leading to a return of Parkinson's symptoms. ### How Entacapone Works

At its core, entacapone works by inhibiting an enzyme called Catechol-O-methyltransferase (COMT). COMT is responsible for breaking down levodopa in the body before it can reach the brain. By blocking COMT, entacapone allows more levodopa to cross the blood-brain barrier, where it is then converted into dopamine – the neurotransmitter deficient in Parkinson

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Entacapone is approved for (FDA label)

Entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease (see CLINICAL PHARMACOLOGY, Clinical Studies). Entacapone tablets effectiveness has not been systematically evaluated in patients with Parkinson’s disease who do not experience end-of-dose “wearing-off”.

Source: Read the full FDA label on DailyMed. Label effective date: May 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Entacapone (FDA label)

Because clinical studies are conducted under widely varying conditions, the incidence of adverse reactions (number of unique patients experiencing an adverse reaction associated with treatment per total number of patients treated) observed in the clinical studies of a drug cannot be directly compared to the incidence of adverse reactions in the clinical studies of another drug and may not reflect the incidence of adverse reactions observed in practice. A total of 1,450 patients with Parkinson’s disease were treated with entacapone tablets in premarketing clinical studies. Included were patients with fluctuating symptoms, as well as those with stable responses to levodopa therapy. All patients received concomitant treatment with levodopa preparations, however, and were similar in other clinical aspects.

Source: FDA prescribing information (DailyMed). Set ID: 56327e32-3b06-4144-91a0-bb1908842e33. SPL document ID: 000701ed-32a2-4b57-acb3-41c3b5ad869e. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Entacapone (FDA label)

Entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.

Source: FDA prescribing information (DailyMed). Set ID: 56327e32-3b06-4144-91a0-bb1908842e33. SPL document ID: 000701ed-32a2-4b57-acb3-41c3b5ad869e. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Entacapone (FDA label)

In vitro studies of human CYP enzymes showed that entacapone inhibited the CYP enzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 microM to over 1,000 microM; an oral 200 mg dose achieves a highest level of approximately 5 microM in people); these enzymes would therefore not be expected to be inhibited in clinical use. In an interaction study in healthy volunteers, entacapone did not significantly change the plasma levels of S-warfarin while the AUC for R-warfarin increased on average by 18% [Cl90 11% to 26%], and the INR values increased on average by 13% [Cl90 6% to 19%]. Nevertheless, cases of significantly increased INR in patients concomitantly using warfarin have been reported during the postapproval use of entacapone tablets. Therefore, monitoring of INR is recommended when entacapone treatment is initiated or when the dose is increased for patients receiving warfarin.

Source: FDA prescribing information (DailyMed). Set ID: 56327e32-3b06-4144-91a0-bb1908842e33. SPL document ID: 000701ed-32a2-4b57-acb3-41c3b5ad869e. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.